A Study of BGM0504 in Participants With Obesity

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Enrollment target: estimated 90 to confirmed 96
    • Primary and study completion dates changed from estimate of Jan 11, 2026 to Jan 14, 2026
    • Start date: Apr 3, 2025 to Apr 9, 2025
    • Eligibility criteria expanded, about 13 words
    • Site details revised
  2. Start date: Apr 9, 2025 to Apr 3, 2025v3
  3. Start date changed from estimate of Apr 8, 2025 to Apr 9, 2025v2
  4. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
Trial Details
NCT Number NCT06911203
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Conditions
(from sponsor)		 Obesity
Related terms Obesity
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov